Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939858 · ClinicalTrials.gov registry record
Bioenergetic Profiling and Cognition in GBM Patients
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 6
- Enrollment target
NCT03939858: Clinical Trial study, sponsored by Wake Forest University Health Sciences.
NCT03939858 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03939858 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
This trial studies the use of blood-based bioenergetic profiling and cognitive testing in assessing patients with glioblastoma undergoing chemoradiation therapy. The purpose of this pilot research study is to find out if it is possible to see changes in participants' mitochondria, parts of a cell that produce energy, that might be associated with changes in participants' brain function after chemoradiation therapy.
Primary Outcome
The primary outcome will be the proportion of patients who are able to have bioenergetic profiling completed at all three time points (baseline, one month after radiotherapy, three months after radiotherapy). The proportion and its 95% confidence interval will be calculated.
Interventions
- PROCEDURE Cognitive Assessment
- DIAGNOSTIC_TEST Blood Collection
- DIAGNOSTIC_TEST Bioenergetic Profiling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-10-24 |
| Est. Completion | 2023-06-09 |
Why NCT03939858 stopped before completion
NCT03939858 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Cognitive Assessment is the first listed.
NCT03939858 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03939858 about?
NCT03939858 is a clinical study titled "Bioenergetic Profiling and Cognition in GBM Patients". This trial studies the use of blood-based bioenergetic profiling and cognitive testing in assessing patients with glioblastoma undergoing chemoradiation therapy. The purpose of this pilot research study is to find out if it is possible to see changes in participants' mitochondria, parts of a cell th...
What is the current status of trial NCT03939858?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2019-10-24. Estimated completion is 2023-06-09.
What interventions are being tested in trial NCT03939858?
The interventions under investigation include: Cognitive Assessment (PROCEDURE), Blood Collection (DIAGNOSTIC_TEST), Bioenergetic Profiling (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03939858?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI